|
|
|
|
|
|
|
31.07.25 - 21:36
|
Genvira and Labskin Receive £1.2 Million ($2.0 Million) UK–Canada Collaboration Award to Advance Immunotherapies for Malignant Melanoma (Business Wire)
|
|
|
OTTAWA, Ontario & YORK, England--(BUSINESS WIRE)--Genvira Biosciences Inc. (“Genvira”), a Canadian innovator in next-generation viral vectors, Labskin Limited (“Labskin”), a leader in 3D in vitro human skin models, and the National Research Council of Canada (NRC) are pleased to announce the launch of a collaborative project to develop novel immunotherapies for malignant melanoma. The collaboration is receiving advisory services and up to £1.2 million ($2.0 million) in funding through the Canada–UK Biomanufacturing of Biologics and Advanced Therapies program. UK participants are supported by Innovate UK, part of UK Research and Innovation (UKRI), while in Canada, support for the project is offered through the NRC Industrial Research Assistance Program (NRC IRAP) and the NRC Collaborative Science and Technology Innovation Program (NRC CSTIP).
Malignant melanoma continues to be a serious global health concern, with an estimated 330,000 new cases and 60,000 deaths each year. This international par...
|
|
|
|
|
28.07.25 - 23:03
|
NRC Health Announces Second Quarter 2025 Results (Business Wire)
|
|
|
Reports third consecutive quarter of sequential TRCV GrowthLINCOLN, Neb.--(BUSINESS WIRE)--National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the second quarter 2025.
CEO Statement
Trent S. Green, Chief Executive Officer of NRC Health, commented: “We're encouraged by our second-quarter results, which demonstrate continued momentum across key areas of our business. In my early weeks as CEO, I've been energized by feedback from both current and prospective customers, particularly their enthusiasm for our product portfolio and appreciation for the service mindset of our associates. To provide additional context on the quarter, we're reinstating our quarterly earnings call, which I hope investors will join tomorrow, July 29, at 10 a.m. ET.”
Additional Information
Total recurring contract value1, or TRCV, grew 2% sequentially, the third consecutive quarter of TRCV growth and the highest sequential growth rate since the first quarter of 2021. New logo sales, cross-sel...
|
|
|
|
|
|
|
|
|
11.06.25 - 07:42
|
Fugaku Remains Top in World Supercomputer Graph500 Ranking (Nippon)
|
|
|
Tokyo, June 11 (Jiji Press)--Japan's Fugaku has remained top in the Graph500 world supercomputer ranking, national research institute Riken said Tuesday. Fugaku, developed by Riken and information technology company Fujitsu Ltd., maintained the lead in Graph500, a benchmark for big data analysis. The supercomputer, located in the western city of Kobe, fell to second in the High Performan......
|
|
|
|
|
04.06.25 - 15:03
|
G7 Representatives Gather in Markham and Toronto to Strengthen Global Semiconductor Partnerships (Business Wire)
|
|
|
ventureLAB Hosts Official Stakeholder Forum and Industry Reception in Markham and TorontoMARKHAM, Ontario--(BUSINESS WIRE)--Representatives from G7 nations convened in Markham and Toronto on June 3 to discuss international collaboration and priorities for the future of semiconductors. The meeting was hosted by ventureLAB, Canada's leading hub for hardware and semiconductor innovation.
Held at ventureLAB's headquarters in Markham, the G7 Semiconductor Point of Contact Group Stakeholder Forum welcomed senior leaders from government, industry, and academia across G7 member countries. The gathering marked a pivotal moment in the ongoing efforts to develop secure, resilient semiconductor supply chains and accelerate economic growth through shared innovation.
The stakeholder forum was led by Innovation, Science and Economic Development Canada (ISED) with support from the National Research Council of Canada (NRC) and Global Affairs Canada (GAC) and included delegates from each of the G7 nations. These forums w...
|
|
|
|
|
|
|
21.05.25 - 12:06
|
ME Therapeutics Receives Support to Advance mRNA Therapeutic Candidates for Cancer and Inflammatory Disease (Business Wire)
|
|
|
VANCOUVER, British Columbia--(BUSINESS WIRE)--ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed preclinical biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, today announced that its subsidiary, ME Therapeutics Inc., is receiving advisory services and up to $140,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The project will support the research and development of ME Therapeutic's mRNA therapeutic program targeting myeloid cell biology for the treatment of cancer and inflammatory disease.
“We are pleased to receive this support from NRC IRAP, which builds on advisory services and funding received in past years, to allow us to further advance preclinical studies for our mRNA therapeutic candidates that target key myeloid cell pathways,” said Salim Dhanji, CEO of ME Therapeutics. “Our team at ME Therapeutics passionately believe...
|
|
|
|
|
09.05.25 - 05:45
|
Innovotech Receives Support to Develop Antimicrobial Testing Services and Product Enhancements (The Newswire)
|
|
|
Edmonton, May 8, 2025 – TheNewswire - Innovotech Inc. (TSX-V: IOT) reports that its subsidiary Innovotech Labs Corporation is receiving advisory services and research and development funding of up to $150,000 CAD from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support the development of new antimicrobial testing services for use with medical devices such as catheters, implants, and wound dressings.
The new testing methods align with upcoming changes in international regulatory standards and medical device manufacturers' needs in the areas of proliferation, biofilm formation, and translocation of microorganisms.
Innovotech Labs Corporation is also receiving funding of up to $30,000 CAD through the NRC IRAP Youth Employment Program to support the hiring of a young graduate to work on the development of antimicrobial silver compounds with properties complementary to InnovoSIL™-1 silver for expanded applications.
“This NRC IRAP support wi...
|
|
|
|
|
|
|
|
|
28.04.25 - 23:03
|
NRC Health Announces First Quarter Results (Business Wire)
|
|
|
LINCOLN, Neb.--(BUSINESS WIRE)--National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2025 and other corporate developments.
Highlights:
Total Recurring Value Contract Value Increases Sequentially
Sales Force Expansion Accelerates
New Share Repurchase Program Announced
Operating Expenses Decline
Dividend Declared
Overview
Michael D. Hays, Chief Executive Officer of NRC Health, commented on the Company's performance and recent developments:
“The key milestone this quarter was a second consecutive quarter of sequential increase in total recurring contract value, which remains the leading indicator of revenue growth. This progress reflects the rebuilding of our sales force - never a quick process, but one that is already delivering results. We are seeing meaningful increases in our pipeline, win rates, and overall sales. Building on this momentum, we are now aggressively accelerating our sales force expansion plans to fully capitalize on our broader prod...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
